Product: MTA1 Antibody
Catalog: DF3258
Description: Rabbit polyclonal antibody to MTA1
Application: WB IHC IF/ICC
Reactivity: Human, Mouse, Rat
Prediction: Pig, Bovine, Horse, Rabbit, Dog, Chicken
Mol.Wt.: 80 KD; 81kD(Calculated).
Uniprot: Q13330
RRID: AB_2835556

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Product Info

WB 1:500-1:1000, IF/ICC 1:100-1:500, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user.

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Pig(88%), Bovine(88%), Horse(88%), Rabbit(88%), Dog(100%), Chicken(88%)
MTA1 Antibody detects endogenous levels of total MTA1.
Cite Format: Affinity Biosciences Cat# DF3258, RRID:AB_2835556.
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.


Metastasis associated 1; Metastasis associated gene 1; Metastasis associated gene 1 protein; Metastasis associated protein; Metastasis associated protein MTA 1; Metastasis associated protein MTA1; Metastasis-associated protein MTA1; MTA 1; MTA1; MTA1_HUMAN;


Q13330 MTA1_HUMAN:

Widely expressed. High expression in brain, liver, kidney, and cardiac muscle, ovaries, adrenal glands and virgin mammary glands. Higher in tumors than in adjacent normal tissue from the same individual. Up-regulated in a wide variety of cancers including breast, liver, ovarian, and colorectal cancer and its expression levels are closely correlated with tumor aggressiveness and metastasis.




Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - Q13330 As Substrate

Site PTM Type Enzyme
Y11 Phosphorylation
K32 Ubiquitination
K98 Ubiquitination
K125 Ubiquitination
K164 Ubiquitination
K182 Ubiquitination
K208 Ubiquitination
S230 Phosphorylation
S231 Phosphorylation
S232 Phosphorylation
R234 Methylation
S241 Phosphorylation
K305 Ubiquitination
K340 Ubiquitination
Y355 Phosphorylation
K361 Ubiquitination
S386 Phosphorylation
Y427 Phosphorylation
S446 Phosphorylation
S449 Phosphorylation
S458 Phosphorylation
S460 Phosphorylation
K462 Ubiquitination
T467 Phosphorylation
K509 Sumoylation
S520 Phosphorylation
S522 Phosphorylation P24941 (CDK2)
K527 Ubiquitination
K532 Methylation
S562 Phosphorylation
T564 Phosphorylation
S576 Phosphorylation
T578 Phosphorylation
K582 Methylation
K582 Ubiquitination
S584 Phosphorylation
R604 Methylation
K626 Acetylation
K626 Ubiquitination
R636 Methylation
S639 Phosphorylation
Y659 Phosphorylation
K670 Ubiquitination
S673 Phosphorylation
S675 Phosphorylation
T677 Phosphorylation
K678 Ubiquitination
Y685 Phosphorylation

Research Backgrounds


Transcriptional coregulator which can act as both a transcriptional corepressor and coactivator. As a part of the histone-deacetylase multiprotein complex (NuRD), regulates transcription of its targets by modifying the acetylation status of the target chromatin and cofactor accessibility to the target DNA. In conjunction with other components of NuRD, acts as a transcriptional corepressor of BRCA1, ESR1, TFF1 and CDKN1A. Acts as a transcriptional coactivator of BCAS3, PAX5 and SUMO2, independent of the NuRD complex. Stimulates the expression of WNT1 by inhibiting the expression of its transcriptional corepressor SIX3. Regulates p53-dependent and -independent DNA repair processes following genotoxic stress. Regulates the stability and function of p53/TP53 by inhibiting its ubiquitination by COP1 and MDM2 thereby regulating the p53-dependent DNA repair. Plays an important role in tumorigenesis, tumor invasion, and metastasis. Involved in the epigenetic regulation of ESR1 expression in breast cancer in a TFAP2C, IFI16 and HDAC4/5/6-dependent manner. Plays a role in the regulation of the circadian clock and is essential for the generation and maintenance of circadian rhythms under constant light and for normal entrainment of behavior to light-dark (LD) cycles. Positively regulates the CLOCK-ARNTL/BMAL1 heterodimer mediated transcriptional activation of its own transcription and the transcription of CRY1. Regulates deacetylation of ARNTL/BMAL1 by regulating SIRT1 expression, resulting in derepressing CRY1-mediated transcription repression. Isoform Short binds to ESR1 and sequesters it in the cytoplasm and enhances its non-genomic responses. With TFCP2L1, promotes establishment and maintenance of pluripotency in embryonic stem cells (ESCs) and inhibits endoderm differentiation (By similarity).


Phosphorylation by CSNK1G2/CK1 triggered by estrogen enhances corepression of estrogen receptor (ER).

Acetylation is essential for its transcriptional coactivator activity.

Sumoylation positively regulates its transcriptional corepressor activity but does not affect the protein stability. Sumoylated preferentially by SUMO2 or SUMO3 than SUMO1. Sumoylation is enhanced by PIAS1/3/4 and preferentially sumoylated by SUMO2 in the presence of PIAS1/3/4. Desumoylated by SENP1.

Ubiquitinated by COP1, which leads to proteasomal degradation.

Subcellular Location:


Nucleus. Nucleus envelope. Cytoplasm. Cytoplasm>Cytoskeleton.
Note: Associated with microtubules. Localization at the nuclear envelope is TPR-dependent.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Widely expressed. High expression in brain, liver, kidney, and cardiac muscle, ovaries, adrenal glands and virgin mammary glands. Higher in tumors than in adjacent normal tissue from the same individual. Up-regulated in a wide variety of cancers including breast, liver, ovarian, and colorectal cancer and its expression levels are closely correlated with tumor aggressiveness and metastasis.

Subunit Structure:

Component of the nucleosome-remodeling and histone-deacetylase multiprotein complex (NuRD). Interacts with HDAC1 and ITGB3BP/CENPR. Binds to CSNK1G2 in the cytoplasm. Interacts with NACC2. Interacts with ARNTL/BMAL1 and CLOCK. Interacts with EP300, TFAP2C, IFI16, TPR, HDAC2, UBE2I/UBC9, PIAS1, PIAS3, PIAS4, p53/TP53, MDM2, COP1, SUMO1, SUMO2, SENP1 and SENP2. Interacts with SIX3; facilitates the binding of SIX3 to the core DNA motif of SIX3 promoter (By similarity). Interacts with TFCP2L1; which is indispensable for TFCP2L1-mediated self-renewal-promoting effect and endoderm-inhibiting action (By similarity).


Isoform Short contains a Leu-Arg-Ile-Leu-Leu motif (ER binding motif).

Restrictive clause


Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.